Re: Stifel Nicolaus Healthcare Conference Call byAppreciate if someone would help me understand the nuances or literal meaning of the following statement made by Mr. Davis (VP Corp Affairs at Endo) on the call...
"Urocidin...that is a product that is entering the second of two phase III studies".
I tend to take comments literally so my question is...
If the above statement from Mr. Davis accurately reflects the Ph III status of Urocidin....does Urocidin have to have "passed" (for lack of better words) the initial phase of the study to progress to the second phase?
I assume there is a protocol followed that would provide the answer to this question. If someone would provide this info it would be appreciated. And, I apologise if the answer has previously been shared...just direct me to the post. Note, you can still access the playback of the call on Endo site. Statement made at about 8:55 into the call.
Thank you,
rg
individual investor (long and deep on BNC)